First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
for PIK3CA Mutation
Sites in New Haven +22 more locations
Sponsor: Relay Therapeutics, Inc.
Sex: All·Age: 18+
Code: NCT05216432·Phase 1·Recruiting·Listed Jan 2022